Drug firms rethink launch sequencing as UK pricing uncertainty continues, warns industry group
This article was originally published in SRA
Executive Summary
Continued uncertainty over an overhaul of the UK's pricing and reimbursement regime is making drug companies rethink their launch sequences for new products and is putting investors off the UK as a top place to conduct clinical development, says Steve Bates, CEO of the BioIndustry Association1-3.